Abbott Wins Antitrust Challenge Over HIV Drug Cocktail

Law360, New York (July 27, 2006, 12:00 AM EDT) -- When patent owners raise prices and make combination products more expensive in the process, they cannot be sued for monopoly leveraging under U.S. antitrust laws, according to a ruling Wednesday by the U.S. Court of Appeals for the Seventh Circuit.

With the ruling, Judge Frank H. Easterbrook affirmed a lower court’s decision that drug maker Abbott Laboratories Inc. wasn’t violating the Sherman Act when it jacked up the price for its component of a treatment for acquired immune deficiency syndrome.

The class action legal battle surrounds...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.